Bristol-Myers Squibb announced that Opdivo (nivolumab injection) has been approved by the China National Medical Products Administration (NMPA), in combination with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urinary tract epithelial cancer in adults. After approval, Opdivo in combination with chemotherapy has become the first and currently the only approved immunotherapy for first-line treatment of advanced urinary tract epithelial cancer in China. Opdivo also becomes the only PD-1 inhibitor with indications covering early adjuvant treatment and advanced first-line treatment of urinary tract epithelial cancer.
百时美施贵宝：欧狄沃联合含顺铂化疗获批尿路上皮癌一线治疗适应症
Bristol-Myers Squibb: Opdivo in combination with cisplatin chemotherapy has been approved for first-line treatment indication in urinary tract epithelial cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated